Search

Objectives Relative efficacy and safety of triple antiplatelet therapy (TAT, addition of cilostazol to aspirin and clopidogrel) compared with conventional dual antiplatelet therapy (DAT, aspirin and clopidogrel) remained controversial. This meta-analysis was performed to compare the risk of cardiac events and restenosis of TAT versus DAT in drug-eluting stents (DES) implantation patients. Methods We performed PUBMED, MEDLINE, EMBASE and Cochrane CENTRAL searches for randomised clinical trials of TAT versus DAT in patients after DES implantation. Five clinical trials (3526 patients) were involved in the meta-analysis. Period of clinical follow-up ranged from 9 to 12 months. Results TAT was associated with a 36% reduction in major adverse cardiac events (MACE) (OR=0.64; 95% CI 0.51 to 0.81, p Conclusions Addition of cilostazol to conventional DAT reduced the incidence of MACE, TVR and TLR in patients after DES implantation. TAT also reduced the risk of angiographic restenosis and late loss in patients after DES implantation.

Objectives Cardiac troponin T elevation after coronary intervention has been demonstrated to be associated with the prognosis of coronary artery disease (CAD). However, there were few studies about comprehensive risk factors analysis of troponin T elevation after elective drug-eluting stent (DES) implantation. Methods From March to December in 2010, patients with stable CAD were admitted for elective coronary intervention in our hospital. They were divided into elevated troponin T group and normal troponin T group by post-procedural troponin T. Clinical factors, laboratory-test factors and angiographic factors (such as gender, age, cholesterol, Gensini score and so on) were analysed. Results A total of 209 patients with an average age of 64.0±9.9 years were enrolled in the study: 70 patients with elevated troponin T (≥0.03 ng/ml) after DES implantation and 139 patients with normal troponin T ( Conclusions Age, serum total cholesterol, number of stenosed vessels and number of implanted stents could be independent risk factors of troponin T elevation after elective DES implantation.